142 related articles for article (PubMed ID: 19073250)
1. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia.
Pannier S; Couloigner V; Messaddeq N; Elmaleh-Bergès M; Munnich A; Romand R; Legeai-Mallet L
Biochim Biophys Acta; 2009 Feb; 1792(2):140-7. PubMed ID: 19073250
[TBL] [Abstract][Full Text] [Related]
2. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
Mugniery E; Dacquin R; Marty C; Benoist-Lasselin C; de Vernejoul MC; Jurdic P; Munnich A; Geoffroy V; Legeai-Mallet L
Hum Mol Genet; 2012 Jun; 21(11):2503-13. PubMed ID: 22367969
[TBL] [Abstract][Full Text] [Related]
3. Hearing loss in a mouse model of Muenke syndrome.
Mansour SL; Twigg SR; Freeland RM; Wall SA; Li C; Wilkie AO
Hum Mol Genet; 2009 Jan; 18(1):43-50. PubMed ID: 18818193
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
[TBL] [Abstract][Full Text] [Related]
5. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
[TBL] [Abstract][Full Text] [Related]
6. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
7. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
8. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
9. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
[TBL] [Abstract][Full Text] [Related]
10. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
12. Proposal of patient-specific growth plate cartilage xenograft model for FGFR3 chondrodysplasia.
Kimura T; Ozaki T; Fujita K; Yamashita A; Morioka M; Ozono K; Tsumaki N
Osteoarthritis Cartilage; 2018 Nov; 26(11):1551-1561. PubMed ID: 30086379
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation.
Gibbs L; Legeai-Mallet L
Biochim Biophys Acta; 2007 Apr; 1773(4):502-12. PubMed ID: 17320202
[TBL] [Abstract][Full Text] [Related]
14. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
15. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
Tanaka H
Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
[TBL] [Abstract][Full Text] [Related]
16. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
Khnykin D; Olsnes S
Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
[TBL] [Abstract][Full Text] [Related]
17. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
18. Hypochondroplasia in a child with 1620C>G (Asn540Lys) mutation in FGFR3.
Korkmaz HA; Hazan F; Dizdarer C; Tükün A
J Clin Res Pediatr Endocrinol; 2012 Dec; 4(4):220-2. PubMed ID: 23149434
[TBL] [Abstract][Full Text] [Related]
19. Loss of Fgfr3 leads to excess hair cell development in the mouse organ of Corti.
Hayashi T; Cunningham D; Bermingham-McDonogh O
Dev Dyn; 2007 Feb; 236(2):525-33. PubMed ID: 17117437
[TBL] [Abstract][Full Text] [Related]
20. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
